Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: Ravulizumab to Protect CKD Patients From CSA-AKI and MAKE
2022-501802-36-00Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in cardiac surgery-associated acute kidney injury (CSA-AKI) and chronic kidney disease (CKD) comparing Ravulizumab (Ultomiris) with Placebo (2 arms). Primary endpoint: MAKE90. Started May 2023; status: completed.
02
Drugs
ravulizumab
03
Conditions
cardiac surgery-associated acute kidney injury (CSA-AKI)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2022-501802-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501802-36-00.